Rose-Zerilli, Matthew - University of Southampton

个人简介

As a cancer geneticist, my research elucidates the natural history of a patient’s cancer at the DNA level with the aim of providing improved clinical prognoses. As Faculty of Medicine Career Track Fellow, I am exploring the power of single-cell analyses to understand more about the evolution of blood cancer and the interaction between different mutations in individual cancer cells. Dr. Matthew Rose-Zerilli graduated from the University of Portsmouth in 2002. He went on to work in the Pharmacogenomics industry at Sciona Inc. as a Research & Development Scientist. In 2003, Matthew returned to academia in Southampton as a research assistant in the Human Genetics Division, Faculty of Medicine. Following his PhD in the Respiratory Genetics Laboratory of Professor John Holloway, Matthew joined the Cancer Genomics laboratory of Professor Jonathan Strefford within the Cancer Sciences Unit in the Faculty of Medicine as a postdoctoral researcher. After two successful postdoctoral positions and through mentorship from Professor Strefford, he is now developing his own research area in cancer genetics.

研究领域

My reseach is focussed in understanding the clonal evolution of Chronic Lymphocytic Leukaemia (CLL) at the genetic level from diagnosis through to progression, treatment and relapse. By utilising next generation sequencing of whole exomes and high-depth targeted re-sequencing I have been investigating the genetic pathogenesis of a progressive subtype of CLL (mutated-IGHV CLL with no poor-risk biomarkers, defining ~30% of all CLL). I have identified regions of the leukaemia cancer genome targeted by gene mutations and copy number changes that elucidate the natural history of a patient’s cancer at the genetic level. I have completed sequential genetic analysis on a cohort of CLL patients and have identified known and novel gene mutation in each patient that tracks from disease diagnosis through to therapy relapse. These DNA mutations have the potential to be used as biomarkers (predictive and/or prognostic) of poor disease outcome in CLL. I will take these mutations forward for single cell genetic analysis to establish the exact clonal evolution of disease, phasing mutations into individual cells and thereby potentially identifying the key cell that drives CLL progression in these patients.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1 - Garcia, Edwin, Hayden, Annette, Birts, Charles, Britton, Edward, Cowie, Andrew, Pickard, Karen, Mellone, Massimiliano, Choh, Clarisa, Derouet, Mathieu, Duriez, Patrick, Noble, Fergus, White, Michael J., Primrose, John, Strefford, Jonathan C., Rose-Zerilli, Matthew, Thomas, Gareth, Ang, Yeng, Sharrocks, Andrew D., Fitzgerald, Rebecca C. and Underwood, Timothy J. Published:2016Publication:Scientific reportsVolume:6, (32417)Page Range:1-12doi:10.1038/srep32417PMID:27600491 Surface IgM expression and function associate with clinical behavior, genetic abnormalities and DNA methylation in CLL - D'Avola, Annalisa, Drennan, Samantha, Tracy, Ian, Henderson, Isla, Chiecchio, Laura, Larrayoz, Marta, Rose-Zerilli, Matthew, Strefford, Jonathan, Plass, Christoph, Johnson, Peter W., Steele, Andrew J., Packham, Graham, Stevenson, Freda K., Oakes, Christopher C. and Forconi, Francesco Published:2016Publication:BloodPage Range:1-25doi:10.1182/blood-2016-03-707786PMID:27301861 Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukemia - Parker, Helen, Rose-Zerilli, Matthew J.J., Larrayoz, Marta, Clifford, Ruth, Edelmann, Jennifer, Blakemore, Stuart, Gibson, Jane, Wang, Jun, Ljungstrom, Viktor, Wojdacz, Tomasz K., Chaplin, Tracy, Roghanian, Ali, Davis, Zadie, Parker, Anton, Tausch, Eugen, Ntoufa, Stavroula, Ramos, Sara, Robbe, Pauline, Alsolami, Reem, Steele, Andrew J., Packham, Graham, Rodriquez-Vicente, Ana E., Brown, Lee, McNicholl, Feargal, Forconi, Francesco, Pettitt, Andrew, Hillmen, Peter, Dyer, Martin, Cragg, Mark S., Chelala, Claude, Oakes, Christopher C., Rosenquist, Richard, Stamatopoulos, Kostas, Stilgenbauer, Stephan, Knight, Samantha, Schuh, Anna, Oscier, David G. and Strefford, Jonathan C. Published:2016Publication:LeukemiaPage Range:1-22 The outcome of chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity - Davis, Zadie, Forconi, Francesco, Parker, Anton, Gardiner, Anne, Thomas, Peter, Catovsky, Daniel, Rose-Zerilli, Matthew, Strefford, Jonathan and Oscier, David Published:2016Publication:British Journal of HaematologyPage Range:1-10doi:10.1111/bjh.13940PMID:26846718